Jul 2026· Advancement of science· 0 citations· 46 references
Medicine
TL;DR
A previously unrecognized transcription‐ubiquitination cascade that modulates Hippo signaling and contributes to breast cancer progression is revealed, highlighting this axis as a candidate therapeutic vulnerability that warrants further validation for limiting metastasis.
Abstract
ABSTRACT Epithelial‐mesenchymal transition (EMT) is a key driver of breast cancer progression, yet the upstream transcriptional and ubiquitin‐mediated mechanisms that modulate Hippo signaling remain incompletely defined. In this study, we identify a regulatory axis in which the transcription factor ZBTB11 promotes breast cancer aggressiveness by enhancing the expression of the F‐box protein FBXO28. ZBTB11 directly binds to the FBXO28 promoter and increases its transcription, leading to elevated FBXO28 protein levels. We show that FBXO28 functions as an E3 ubiquitin ligase that targets the core Hippo kinase MST1 for K48‐linked ubiquitination and proteasomal degradation. Reduction of MST1 diminishes Hippo pathway activity, resulting in decreased phosphorylation and enhanced nuclear accumulation of Yes‐associated protein (YAP) and transcriptional coactivator with PDZ‐binding motif (TAZ), which subsequently activates EMT‐related gene expression. Functionally, disruption of the ZBTB11‐FBXO28‐MST1 axis suppresses EMT, migration, invasion, and tumor growth in vitro and in vivo, whereas reintroduction of FBXO28 or depletion of MST1 reverses these effects. Together, our findings reveal a previously unrecognized transcription‐ubiquitination cascade that modulates Hippo signaling and contributes to breast cancer progression, highlighting this axis as a candidate therapeutic vulnerability that warrants further validation for limiting metastasis.
It is shown that the transcriptional cofactor LBH drives mutation-independent Wnt activation and malignant progression in GC via a tumour microenvironment-regulated post-translational stabilization mechanism, elucidate a critical tumour–stroma crosstalk mechanism and establish the targeted disruption of the LBH–β-caten...
Zhi-Xiong Su, Guifeng Zhang, J. Zhong et al.· Cell Death & Disease· 0 citations
ABSTRACT Deregulated alternative splicing (AS) is a hallmark of hepatocellular carcinoma (HCC), yet the specific splicing factors driving oncogenic programs remain largely uncharacterized. Here, we identify RNA‐binding motif protein 25 (RBM25) as a potent oncogenic driver that is overexpressed in HCC and correlates wit...
Wen-Jing Zhang, Li-Li Zhi, Tian Huang et al.· Advancement of science· 0 citations
The ubiquitin signaling cascade plays a pivotal role in multiple cancer types, yet its role in melanoma progression remains incompletely elucidated. An unbiased and systematic analysis indicates that Ubiquitin-specific peptidase 10 (USP10), a member of USP gene family, was top priority prognostic signature for primary...
Zhi-Yuan Qiu, Cheng-Lian Sun, Juan Wang et al.· International Journal on Bio...· 0 citations
Findings identify a novel PRDX1-PRMT5 axis that activates Wnt/β-catenin signaling, highlighting a potential therapeutic strategy for CRC by targeting this pathway to suppress tumor progression and remodel the immune microenvironment.
Nianhua Yu, Xi Li, Jin-Li Han et al.· International Journal of Bio...· 0 citations
ABSTRACT 5‐Methylcytosine (m5C) is a vital RNA modification that regulates mRNA stability, splicing, and nuclear export. As a key m5C reader, ALYREF promotes tumorigenesis across various cancers; however, its precise role in endometrial cancer (EC) remains unknown. ALYREF expression and clinical significance in EC were...
Lin-Lin Hao, Jian Zhang, Qi Qian et al.· Advancement of science· 0 citations
ZEB1 is a key driver of breast cancer pathogenesis and therapy resistance, largely through its ability to promote cancer stem cells (CSCs). Although tumor-secreted cytokines such as IL-6 are known to support tumor progression, how their expression is regulated by upstream transcriptional factors such as ZEB1 remains in...
Wei-Yue Zhang, Yifan Zhou, Wei Ma et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.